Literature DB >> 7042294

Rate-controlled drug dosage.

J Urquhart.   

Abstract

Mesh:

Substances:

Year:  1982        PMID: 7042294     DOI: 10.2165/00003495-198223030-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  57 in total

1.  Elementary osmotic pump.

Authors:  F Theeuwes
Journal:  J Pharm Sci       Date:  1975-12       Impact factor: 3.534

2.  AN EVALUATION OF DOUBLE-BLIND IDU THERAPY IN 100 CASES OF HERPETIC KERATITIS.

Authors:  P R LAIBSON; I H LEOPOLD
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1964 Jan-Feb

3.  The effects of particle size on the absorption of phenacetin in man. A correlation between plasma concentration of phenacetin and effects on the central nervous system.

Authors:  L F Prescott; R F Steel; W R Ferrier
Journal:  Clin Pharmacol Ther       Date:  1970 Jul-Aug       Impact factor: 6.875

4.  Effect of dosage regimen on natriuretic response to furosemide.

Authors:  T W Wilson; K J Falk; J L Labelle; K B Nguyen
Journal:  Clin Pharmacol Ther       Date:  1975-08       Impact factor: 6.875

5.  Prevention of experimental motion sickness by scopolamine absorbed through the skin.

Authors:  A Graybiel; J Knepton; J Shaw
Journal:  Aviat Space Environ Med       Date:  1976-10

6.  Comparison of selected intravenous infusion pumps and rate regulators.

Authors:  J G Kitrenos; M Jones; D C McLeod
Journal:  Am J Hosp Pharm       Date:  1978-03

7.  Impact of continuously administered catechol estrogens on uterine growth and luteinizing hormone secretion.

Authors:  C P Martucci; J Fishman
Journal:  Endocrinology       Date:  1979-12       Impact factor: 4.736

8.  Long-term clinical effects, bioavailability, and kinetics of minoxidil in relation to renal function.

Authors:  D T Lowenthal; G Onesti; R Mutterperl; M Affrime; E W Martinez; K E Kim; P Busby; J Shirk; C Swartz
Journal:  J Clin Pharmacol       Date:  1978-10       Impact factor: 3.126

9.  Evaluation of a prototype therapeutic system for prolonged, continuous topical delivery of homosulfanilamide in the management of Pseudomonas burn wound sepsis.

Authors:  L M Vistnes; E E Schmitt; G A Ksander; E H Rose; W J Balkenhol; C L Coleman
Journal:  Surgery       Date:  1976-06       Impact factor: 3.982

10.  Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty.

Authors:  W F Crowley; F Comite; W Vale; J Rivier; D L Loriaux; G B Cutler
Journal:  J Clin Endocrinol Metab       Date:  1981-02       Impact factor: 5.958

View more
  7 in total

Review 1.  Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.

Authors:  Zohar Nachum; Avi Shupak; Carlos R Gordon
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 2.  Acute overdose with sustained release drug formulations. Perspectives in treatment.

Authors:  A Minocha; D A Spyker
Journal:  Med Toxicol       Date:  1986 Jul-Aug

3.  The role of clinical pharmacology in the development and evaluation of oral controlled-release dosage forms.

Authors:  M J Kendall; V A John
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

Review 4.  Novel oral drug formulations. Their potential in modulating adverse effects.

Authors:  A T Florence; P U Jani
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

5.  Transdermal clonidine application: long-term results in essential hypertension.

Authors:  H Groth; H Vetter; J Knüsel; E Foerster; W Siegenthaler; W Vetter
Journal:  Klin Wochenschr       Date:  1984-10-01

Review 6.  Transdermal hyoscine (Scopolamine). A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  S P Clissold; R C Heel
Journal:  Drugs       Date:  1985-03       Impact factor: 9.546

Review 7.  Controlled release drugs in overdose. Clinical considerations.

Authors:  N A Buckley; A H Dawson; D A Reith
Journal:  Drug Saf       Date:  1995-01       Impact factor: 5.606

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.